Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in ALL
NCT03739814Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2019
- Primary completion
- Feb 2027
- Modality
- scFv Fragments, Monoclonal Antibodies, Bispecific Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of inotuzumab ozogamicin, blinatumomab and ponatinib in acute lymphoblastic leukemia (ALL) (3 cohorts), sponsored by National Cancer Institute. Primary endpoints: Event-free survival at 1 year and Completion of protocol treatment up to 10 years. Started May 2019; status: recruiting.
02
Drugs
inotuzumab ozogamicinblinatumomabponatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03739814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739814.